A novel and potent imidazo[4,5-c] quinolone derivative (NVP-BEZ235), which has entered phase I/II clinical trials in patients with advanced solid tumors, has a potential role in cisplatin-sensitive cancers by dual targeting of the PI3-K (phosphatidylinositol 3-kinase) and mTOR (mammalian target of rapamycin) kinases for NPC treatment
2 Early symptoms may include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, which may progress to more severe manifestations, including jaundice, hepatic encephalopathy, and coagulopathy in patients with advanced liver injury
The role of the microbiota in sedentary lifestyle disorders and ageing: lessons from the animal kingdom
Neurosci Res
2 Mass spectrometric analysis of the LDOX oxidation product flavan-3,3,4-triol (4)
For a more detailed research summary, see our CJC-1295 + ipamorelin GH stack research guide and our what are peptides explainer